Cancer Biotech Bellicum Soars After $140M IPO Trumps Range
Cancer-focused drug company Bellicum Pharmaceuticals Inc. raised $140 million Thursday through an upsized initial public offering — which subsequently soared in its debut — adding momentum for biotech IPOs as a...To view the full article, register now.
Already a subscriber? Click here to view full article